Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Biochemical Pharmacology

• Publication date

  2008-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BCP.2007.09.005PMID 17936723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors

  2006cited by this paper
• Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.

  2005cited by this paper
• A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

  2005cited by this paper
• Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.

  2005cited by this paper
• Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism

  2005cited by this paper
• Late complications of an ileal pouch

  2005cited by this paper
• Cyclooxygenase‐2 inhibitor celecoxib augments chemotherapeutic drug‐induced apoptosis by enhancing activation of caspase‐3 and ‐9 in prostate cancer cells

  2005cited by this paper
• Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells

  2005cited by this paper
• Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.

  2005cited by this paper
• Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells

  2005cited by this paper
• Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.

  2004cited by this paper
• Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription.

  2004cited by this paper
• Cyclooxygenase-2 Promotes Human Cholangiocarcinoma Growth

  2004cited by this paper
• 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells

  2004cited by this paper
• Role of cyclooxygenase-2 in colorectal cancer

  2004cited by this paper
• Cyclooxygenase-2 and its role in colorectal cancer development

  2004cited by this paper
• Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.

  2003cited by this paper
• Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

  2003cited by this paper
• Cyclooxygenase 2: a molecular target for cancer prevention and treatment.

  2003cited by this paper
• Characterization of celecoxib and valdecoxib binding to cyclooxygenase.

  2003cited by this paper
• Regulation of Cyclooxgenase-2 mRNA Stability by Taxanes

  2003cited by this paper
• Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites

  2003cited by this paper
• Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference

  2003cited by this paper
• Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.

  2003cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

  2002cited by this paper
• Celecoxib: a specific COX-2 inhibitor with anticancer properties.

  2002cited by this paper
• Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.

  2002cited by this paper
• Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.

  2002cited by this paper
• Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel.

  2002cited by this paper
• Aspirin‐Induced Inhibition of Ovarian Tumor Cell Growth

  2002cited by this paper
• Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer

  2002cited by this paper
• Single‐dose and steady‐state pharmacokinetics of celecoxib in children

  2002cited by this paper
• Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-dependent Protein Kinase-1 Activity in the Human Colon Cancer HT-29 Cell Line*

  2002cited by this paper
• Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.

  2001cited by this paper
• Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.

  2001cited by this paper
• Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2

  2000cited by this paper
• The relationship between cyclooxygenase-2 expression and colorectal cancer.

  1999cited by this paper
• Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

  1999cited by this paper
• Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.

  1998cited by this paper
• Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

  1998cited by this paper
• The Bradford method for protein quantitation.

  1994cited by this paper
• A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

  1991cited by this paper
• The bradford method for protein quantitation.

  1988cited by this paper
• Comparative properties of five human ovarian adenocarcinoma cell lines.

  1985cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Characterization of WiDr: A human colon carcinoma cell line

  1979cited by this paper
• Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.

  1977cited by this paper

• Celecoxib enhances the response of tumor cells to cisplatin through upregulating PUMA in non–small cell lung cancer carrying wild-type p53

  2024cites this paper
• Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity.

  2023cites this paper
• Repurposing celecoxib for colorectal cancer targeting via pH-triggered ultra-elastic nanovesicles: Pronounced efficacy through up-regulation of Wnt/β-catenin pathway in DMH-induced tumorigenesis

  2023cites this paper
• Formulation, optimization, and characterization of whey protein isolate nanocrystals for celecoxib delivery

  2021cites this paper
• NSAIDs: Old Acquaintance in the Pipeline for Cancer Treatment and Prevention─Structural Modulation, Mechanisms of Action, and Bright Future.

  2021cites this paper
• Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance

  2018cites this paper
• Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.

  2018cites this paper
• Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells

  2018cites this paper
• Cyclooxygenase Inhibitors in Epithelial Ovarian Cancer Treatment

  2018cites this paper
• RGS10 Regulates the Expression of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha through a G Protein–Independent Mechanism

  2018cites this paper
• Clinico-Pathological Significances of Snail 1 & Cox 2 Co-Expression in Serous Ovarian Carcinoma

  2017cites this paper
• Heartwood of Secang (CAESALPINIA SAPPAN L.) Ethanolic Extract Show Selective Cytotoxic Activities on T47D and Widr Cells But Not on Hela Cells

  2017cites this paper
• DEVELOPMENT AND OPTIMIZATION OF CHITOSAN-CA-PECTINATE BEADS OF AMORPHOUS CELECOXIB BY RESPONSE SURFACE METHODOLOGY

  2017cites this paper
• COX-2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression

  2017cites this paper
• COX‐2 inhibitor NS‐398 suppresses doxorubicin‐induced p53 accumulation through inhibition of ROS‐mediated Jnk activation

  2016cites this paper
• Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma

  2016cites this paper
• Calcium Alginate and Calcium Alginate-Chitosan Beads Containing Celecoxib Solubilized in a Self-Emulsifying Phase

  2016cites this paper
• Calcium alginate multi-unit oral dosage form for delayed release of celecoxib

  2015cites this paper
• Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance

  2015cites this paper
• Potential interactions of prescription and over‐the‐counter medications having antioxidant capabilities with radiation and chemotherapy

  2015cites this paper
• Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ET(B) receptor cascade.

  2014cites this paper
• Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts

  2014cites this paper
• Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance

  2014cites this paper
• In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines

  2013cites this paper
• Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs.

  2013cites this paper
• Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.

  2012cites this paper
• Metronomic therapy for gynecologic cancers.

  2012cites this paper
• Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.

  2012cites this paper
• Effect of celecoxib on proliferation, collagen expression, ERK1/2 and SMAD2/3 phosphorylation in NIH/3T3 fibroblasts.

  2012cites this paper
• Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells

  2011cites this paper
• Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model

  2011influential citation
• Celecoxib Antagonizes the Cytotoxicity of Cisplatin in Human Esophageal Squamous Cell Carcinoma Cells by Reducing Intracellular Cisplatin Accumulation

  2011influential citation
• The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer.

  2011cites this paper
• Celecoxib suppresses fibroblast proliferation and collagen expression by inhibiting ERK1/2 and SMAD2/3 phosphorylation.

  2011cites this paper
• Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.

  2011cites this paper
• Microsoft Word-27333839-file00

  2010influential citation
• Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques.

  2010cites this paper
• Cyclooxygenase‐2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer

  2010cites this paper
• Lipid mediators in the prevention and therapy of neuroblastoma

  2009cites this paper
• Celecoxib Potentiates the Anticancer Effect of Cisplatin on Vulvar Cancer Cells Independently of Cyclooxygenase

  2009cites this paper
• The Involvement of the Cyclooxygenase Enzymes in the Gallus Domesticus Model of Ovarian Cancer

  2008influential citation